SEC Form 4 · accession 0000905718-18-000012
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Scott Praill
Officer — Chief Financial Officer
Period of report
Dec 31, 2017
Accepted (ET)
Jan 3, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2017 | J | 211 | $3.20 | A | 47,577 | D | |
| Common StockF2 | Dec 31, 2017 | C | 25,000 | — | A | 72,577 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exchangeable SharesF2 | — | Dec 31, 2017 | C | 25,000 | D | — | — | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
- F2Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock.